# Using OCZ103-OS in Patients With Unresectable and Locally Recurrent or Metastatic Colorectal Cancer Undergoing Standard Chemotherapy

> **NCT01378143** · PHASE2 · COMPLETED · sponsor: **Oncozyme Pharma Inc.** · enrollment: 53 (actual)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** OCZ103-OS [pentamidine bis(2-hydroxyethanesulfonate)], mFOLFOX6 or FOLFIRI

## Key facts

- **NCT ID:** NCT01378143
- **Lead sponsor:** Oncozyme Pharma Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-03
- **Primary completion:** 2014-03
- **Final completion:** 2014-07
- **Target enrollment:** 53 (ACTUAL)
- **Last updated:** 2014-10-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01378143

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01378143, "Using OCZ103-OS in Patients With Unresectable and Locally Recurrent or Metastatic Colorectal Cancer Undergoing Standard Chemotherapy". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01378143. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*